A Look At Four Stocks Down In Last Trading Session of 2015

Anavex Life Sciences Corp. (NASDAQ:AVXL) is extending its losses for the third consecutive day, sliding by another 11% on Thursday. A couple of days ago, Anavex Life Sciences Corp. (NASDAQ:AVXL) said that it has received a subpoena from the Securities and Exchange Commission, which, the company believes to be related to the “unusual activity in the market for the Company’s shares”. Earlier today reports emerged stating that the Pomerantz Law Firm plans to pursue a class action lawsuit against Anavex Life Sciences Corp. (NASDAQ:AVXL), alleging that several directors and executives had violated sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Among the funds we track, none has reported holding shares of Anavex Life Sciences Corp.

Finally, shares of Flamel Technologies S.A. (ADR) (NASDAQ:FLML)  have plunged by nearly 13% amid news that the US Food and Drug Administration has approved a Neostigmine Methylsulfate drug, which may compete with Flamel’s existing product, Bloxiverz. The stock has fallen on a trading volume considerably higher than the average, so investors are probably worried about the impact that the competition will have on Flamel’s sales. Bloxiverz represents a Neostigmine Methylsulfate Injection that is used in the operating room to reverse effects of non-depolarizing neuromuscular blocking agents after a surgery and it is one of Flamel Technologies S.A. (ADR) (NASDAQ:FLML)’s key products. A total of 13 funds from our database reported long positions in Flamel Technologies S.A. (ADR) (NASDAQ:FLML) in the last round of 13F filings, amassing nearly 29% of the company’s outstanding stock.

Correction: An earlier version of this article might have suggested that the discussed stocks were down for the entire 2015. It also stated that the subpoena received by Anavex Life Sciences Corp was related to the violation of the sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Disclosure: none